Advancing Hepatitis C Treatment: Optimizing Care and Outcomes
CE Information
1.0 CME creditCompletion Time
1 hourAvailable Until
March 7, 2026Posted By
Arkansas Academy of Physician Assistants
Navigate
Overview
Specialties
Family Medicine, Infectious Disease, and Primary CareClinical Topics
Hepatitis, Infectious Disease, and PharmacologyThis presentation will explore the latest advancements in Hepatitis C treatment, focusing on evidence-based approaches to optimize patient care and improve treatment outcomes. Topics will include updated guidelines, the role of direct-acting antivirals, and the importance of interdisciplinary care in achieving sustained virologic response (SVR) and long-term patient wellness.
Learning Objectives
-
Review and interpret current Hepatitis C screening and treatment guidelines to ensure alignment with best practices in patient care.
- Examine the mechanisms, efficacy, and safety profiles of direct-acting antivirals in the treatment of Hepatitis C.
- Evaluate and monitor treatment outcomes, including achieving sustained virologic response (SVR), and identify key indicators for long-term success in Hepatitis C management.
- Discuss the role of interdisciplinary teams in optimizing treatment outcomes and supporting long-term patient health in Hepatitis C management.
Speakers
Dr. Gabriella Douglass- PharmD, BCACP, AAHIVP, BC-ADM, TTS, ACUE is the residency program director of the PGY1 and PGY2 pharmacy residency programs at ARcare. She received her Doctor of Pharmacy degree from the University of Tennessee College of Pharmacy and completed a post-doctoral residency in ambulatory care through Harding University and ARcare. Dr. Douglass has practiced in community and primary care pharmacy settings for sixteen years. She maintains a practice site at ARcare, where she works closely with an interdisciplinary team of clinicians to provide comprehensive medication management services for people with or at risk for HIV and Hepatitis C. Dr. Douglass is a Board-Certified Ambulatory Care Pharmacist and is credentialed as an HIV Pharmacist by the American Academy of HIV Medicine.
CE Information
This activity offers 1.0 CME credit to attendees.
Accredited by AAPA.
This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 22 AAPA Category 1 CME credits. Approval is valid from 3/26/2025 to 3/7/2026 . PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-2013092.
Activity Content
Registration to this activity includes access to the following supporting materials.
- Advancing Hepatitis C Treatment: Optimizing Care and Outcomes (Size: 3.12 MB)
Duration: about 1 hour | Quality: HD
11 questions
Access your certificate